Vivos Therapeutics Secures FDA 510(k) Clearance To Treat Moderate To Severe Pediatric Sleep Apnea And Snoring
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics has received FDA 510(k) clearance for its DNA appliance to treat moderate to severe pediatric sleep apnea and snoring in children aged 6 to 17. This approval could enhance Vivos' market position in pediatric sleep disorder treatments.
September 18, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vivos Therapeutics has obtained FDA 510(k) clearance for its DNA appliance, allowing it to treat moderate to severe pediatric sleep apnea and snoring. This regulatory approval could strengthen Vivos' position in the pediatric sleep disorder market.
The FDA 510(k) clearance is a significant regulatory milestone for Vivos Therapeutics, allowing them to market their DNA appliance for pediatric sleep apnea. This could lead to increased sales and market share in the pediatric segment, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100